Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BY 4.0Clinical Rheumatology

Time to first recurrent thrombosis in adults with thrombotic antiphospholipid syndrome: a registry-based retrospective cohort study

  • María Clara Escobar-Millán1
  • Simón Correa-Sierra1
  • Sebastian Hoyos-Gutierrez1
  • Laura Lopez-Correa1
  • Carolina Ochoa-Gallego1
  • Diana Rocío Gil Calderón2,3
  • Juan Camilo Díaz-Coronado1,2
  • Diego Fernando Rojas-Gualdrón1
  1. 1Facultad de Ciencias de La Salud, Universidad CES, Calle 10ª # 22-04 Bloque C Piso 2 Facultad de Ciencias de la Salud, Medellín, Colombia
  2. 2ARTMEDICA IPS, Medellín, Colombia
  3. 3Hospital Universitario Mayor-MEDERI – Universidad El Rosario, Bogotá, Colombia
Read full textPDFDOICite

Abstract

Objective: To estimate time to first recurrent thrombosis and to explore the association between recurrent thrombosis and clinical, laboratory/immunological, and treatment-related factors among Colombian adults with thrombotic antiphospholipid syndrome (APS) enrolled in the ARTMEDICA autoimmune diseases program (2013–2024).

Methods: We conducted a registry-based retrospective follow-up study of patients with thrombotic APS. Patients were followed from the index thrombotic event to the first recurrent arterial or venous thrombosis. Time-to-event analyses used interval-censored parametric survival regression with a log-logistic distribution. To explore factors associated with recurrence, we also applied a matched nested case–control design using conditional logistic regression.

Results: We included 355 patients (mean follow-up 6.6 years), 71.0% female, median age 47 years (IQR 32–60). Primary APS accounted for 83.4% of cases, and the index event was arterial in 72.1%. During follow-up, 130 patients experienced a first thrombotic recurrence: 70.8% venous. The 10-year probability of first recurrence was 42% (95% CI 28.4–55.5%), with 20% (95% CI 10.5–29.1%) during the first 2 years. In the nested case–control, recurrent thrombosis was significantly associated with the LA + /aCL + /antiβ2GPI − profile (OR 4.8; p = 0.044), male sex (OR 1.8; p = 0.038), prior gestational death (OR 2.4; p = 0.008), and ANA positivity (OR 2.4; p = 0.015).

Conclusions: The risk of recurrent thrombosis was highest during the first 2 years after the index thrombotic event, supporting an early vulnerable phase and underscoring the need for closer clinical surveillance and secondary prevention. Limitations of the study include its retrospective design, the lack of standardized anticoagulation monitoring and residual confounding.

Key Points

• Thrombotic APS carries a high early recurrence burden despite anticoagulation, particularly during the first 2 years after the index event.

• Early identification of high-risk patients and intensive surveillance may be critical to prevent recurrent thrombosis.

Related

  1. Beyond thrombosis: a scoping review of patient-reported outcomes in antiphospholipid syndrome
    Chanakya Nayudu, Andrew Song, Shruti Chaturvedi
    Blood vessels, thrombosis & hemostasisPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. May Thurner Syndrome (MTS), A Rare Cause of Recurrent Lower Extremity Deep Venous Thrombosis (DVT)
    Amir Rashid, Karamat Ali, Attia Khaliq +1
    Pakistan Armed Forces Medical JournalPeer-reviewedCC BY-NCFull textSurgery & anaesthesiaDOAJ
  3. ANTIBODIES AND PLASMA COMPONENTS CONTRIBUTE DIFFERENTLY TO PLATELET REACTIVITY IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME
    Bruna Cardoso JACINTHO-ROBISON, Guilherme Garcia RAFAEL, Rafaela Gomes FRANÇA +5
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
  4. Antiphospholipid Syndrome as an Under-Recognized Cause of Ischemic Stroke in Older Adults: A Retrospective Case Series.
    Seyed Mostafa Razavi, Mahika Khurana, Mariami Gabadadze +4
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Case Report: Recurrent Kounis syndrome complicated with acute coronary stent thrombosis
    Yong Li, Chuanwen Jiang, Xiaojun Zhou +1
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{escobarmillan2026time,
  title = {{Time to first recurrent thrombosis in adults with thrombotic antiphospholipid syndrome: a registry-based retrospective cohort study}},
  author = {María Clara Escobar-Millán and Simón Correa-Sierra and Sebastian Hoyos-Gutierrez and Laura Lopez-Correa and Carolina Ochoa-Gallego and Diana Rocío Gil Calderón and Juan Camilo Díaz-Coronado and Diego Fernando Rojas-Gualdrón},
  journal = {Clinical Rheumatology},
  year = {2026},
  month = sep,
  doi = {10.1007/s10067-026-08372-9},
  url = {https://doi.org/10.1007/s10067-026-08372-9},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Time to first recurrent thrombosis in adults with thrombotic antiphospholipid syndrome: a registry-based retrospective cohort study
AU  - María Clara Escobar-Millán
AU  - Simón Correa-Sierra
AU  - Sebastian Hoyos-Gutierrez
AU  - Laura Lopez-Correa
AU  - Carolina Ochoa-Gallego
AU  - Diana Rocío Gil Calderón
AU  - Juan Camilo Díaz-Coronado
AU  - Diego Fernando Rojas-Gualdrón
PY  - 2026
DA  - 2026/09/08
JO  - Clinical Rheumatology
DO  - 10.1007/s10067-026-08372-9
UR  - https://doi.org/10.1007/s10067-026-08372-9
AB  - Objective: To estimate time to first recurrent thrombosis and to explore the association between recurrent thrombosis and clinical, laboratory/immunological, and treatment-related factors among Colombian adults with thrombotic antiphospholipid syndrome (APS) enrolled in the ARTMEDICA autoimmune diseases program (2013–2024).  Methods: We conducted a registry-based retrospective follow-up study of patients with thrombotic APS. Patients were followed from the index thrombotic event to the first recurrent arterial or venous thrombosis. Time-to-event analyses used interval-censored parametric survival regression with a log-logistic distribution. To explore factors associated with recurrence, we also applied a matched nested case–control design using conditional logistic regression.  Results: We included 355 patients (mean follow-up 6.6 years), 71.0% female, median age 47 years (IQR 32–60). Primary APS accounted for 83.4% of cases, and the index event was arterial in 72.1%. During follow-up, 130 patients experienced a first thrombotic recurrence: 70.8% venous. The 10-year probability of first recurrence was 42% (95% CI 28.4–55.5%), with 20% (95% CI 10.5–29.1%) during the first 2 years. In the nested case–control, recurrent thrombosis was significantly associated with the LA + /aCL + /antiβ2GPI − profile (OR 4.8; p = 0.044), male sex (OR 1.8; p = 0.038), prior gestational death (OR 2.4; p = 0.008), and ANA positivity (OR 2.4; p = 0.015).  Conclusions: The risk of recurrent thrombosis was highest during the first 2 years after the index thrombotic event, supporting an early vulnerable phase and underscoring the need for closer clinical surveillance and secondary prevention. Limitations of the study include its retrospective design, the lack of standardized anticoagulation monitoring and residual confounding.  Key Points  • Thrombotic APS carries a high early recurrence burden despite anticoagulation, particularly during the first 2 years after the index event.  • Early identification of high-risk patients and intensive surveillance may be critical to prevent recurrent thrombosis.
SN  - 0770-3198
SN  - 1434-9949
ER  -